Diamyd Medical AB (FRA:DMN) Research & Development: €19.41 Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DMN Diamyd Medical AB FRA:DMN
41 GF Score
Price €0.07
GF Value €0.07
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Diamyd Medical AB Research & Development?

Diamyd Medical AB FRA:DMN -3.97% 41 Research & Development is €19.41 Mil as of May. 2026. GuruFocus rates FRA:DMN with a GF Score™ of 41/100 and a GF Value™ of €0.07 (Fairly Valued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Diamyd Medical AB's Research & Development for the three months ended in May. 2026 was €9.67 Mil. Its Research & Development for the trailing twelve months (TTM) ended in May. 2026 was €19.41 Mil.

Diamyd Medical AB  (FRA:DMN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Diamyd Medical AB Research & Development Related Terms

Diamyd Medical AB Research & Development Historical Data

* Premium members only.

The historical data trend for Diamyd Medical AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB Research & Development Chart

Diamyd Medical AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.57 7.19 5.92 8.42 10.72

Diamyd Medical AB Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.91 2.73 2.77 4.24 9.67
FRA:DMN
41GF Score
Diamyd Medical AB FRA:DMN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamyd Medical AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €19.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €19.41 Mil mean?
Diamyd Medical AB (FRA:DMN) has a Research & Development of €19.41 Mil as of May. 2026. Research and development expense is the total cost for research and development activities. View historical data on Diamyd Medical AB and its competitors.
Is Diamyd Medical AB's Research & Development too high?
Diamyd Medical AB's current Research & Development is €19.41 Mil. Overall, Diamyd Medical AB has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Research & Development compare to VRTX and REGN?
Diamyd Medical AB's Research & Development of €19.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Diamyd Medical AB and its competitors. Diamyd Medical AB's current Research & Development is €19.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (FRA:DMN) is currently considered Fairly Valued. The stock's GF Value™ is €0.07, compared to a current price of €0.07 — trading 3.6% above its estimated fair value. The current Research & Development is €19.41 Mil. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Diamyd Medical AB (FRA:DMN), the current Research & Development is €19.41 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?

Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be overvalued. The current stock price of €0.07 is trading 3.6% above its estimated GF Value™ of €0.07. GuruFocus considers Diamyd Medical AB to be Fairly Valued.

Key valuation signals for FRA:DMN:

  • Research & Development: €19.41 Mil
  • GF Value™: €0.07 vs. price of €0.07 (3.6% above fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diamyd Medical AB Business Description

Other Exchanges DMYD B:Sweden
Address Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score

Get the complete analysis for FRA:DMN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.07
GF Value